Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy

被引:64
作者
Cavelier, Cindy [1 ,2 ]
Didier, Christine [1 ,2 ]
Prade, Nais [3 ]
Mas, Veronique Mansat-De [3 ,4 ]
Manenti, Stephane [3 ]
Recher, Christian [3 ,4 ]
Demur, Cecile [3 ,4 ]
Ducommun, Bernard [1 ,2 ,4 ]
机构
[1] Univ Toulouse, LBCMCP, Toulouse, France
[2] CNRS, LBCMCP, UMR5088, Toulouse, France
[3] Inst Natl Sante & Rech Med, Ctr Physiopathol Toulouse Purpan, U563, Toulouse, France
[4] CHU Toulouse Purpan, Hematol Lab, TSA 40031, Toulouse, France
关键词
HISTONE H2AX PHOSPHORYLATION; DEPENDENT KINASE INHIBITOR; PHASE-I TRIAL; CELL-CYCLE; UCN-01; SURVIVAL; AML; POOR; CHK1; 7-HYDROXYSTAUROSPORINE;
D O I
10.1158/0008-5472.CAN-09-0939
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Genomic instability in solid tumors participates in the oncogenetic process and is associated with the activation of the DNA damage response pathway. Here, we report the activation of the constitutive DNA damage and checkpoint pathway associated with complex karyotypes in samples from patients with acute myeloid leukemia (AML). We show that antagonizing CHK1 kinase with a small inhibitory compound or by RNA interference strongly reduces the clonogenic properties of high-DNA damage level AML samples, particularly those with complex karyotypes. Moreover, we observe a beneficial effect of CHK1 inhibition in high-DNA damage level AML samples treated with 1-beta-D-arabinofuranosyleytosine. In contrast, CHK1 inhibition has no effect on the clonogenic properties of normal hematopoietic progenitors. All together, our results indicate that CHK1 inhibition may represent an attractive therapeutic opportunity in AML with complex karyotype. [Cancer Res 2009;69(22):8652-61]
引用
收藏
页码:8652 / 8661
页数:10
相关论文
共 39 条
[1]  
Bardet V, 2006, HAEMATOLOGICA, V91, P757
[2]   Chk1 and Chk2 kinases in checkpoint control and cancer [J].
Bartek, J ;
Lukas, J .
CANCER CELL, 2003, 3 (05) :421-429
[3]   DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis [J].
Bartkova, J ;
Horejsi, Z ;
Koed, K ;
Krämer, A ;
Tort, F ;
Zieger, K ;
Guldberg, P ;
Sehested, M ;
Nesland, JM ;
Lukas, C ;
Orntoft, T ;
Lukas, J ;
Bartek, J .
NATURE, 2005, 434 (7035) :864-870
[4]   The when and wheres of CDC25 phosphatases [J].
Boutros, R ;
Dozier, C ;
Ducommun, B .
CURRENT OPINION IN CELL BIOLOGY, 2006, 18 (02) :185-191
[5]   CDC25B involvement in the centrosome duplication cycle and in microtubule nucleation [J].
Boutros, Rose ;
Lobjois, Valerie ;
Ducommun, Bernard .
CANCER RESEARCH, 2007, 67 (24) :11557-11564
[6]  
Brady N, 2003, CANCER RES, V63, P1798
[7]   Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia [J].
Braess, J ;
Jahns-Streubel, G ;
Schoch, C ;
Haase, D ;
Haferlach, T ;
Fiegl, M ;
Voss, S ;
Kern, W ;
Schleyer, E ;
Hiddemann, W .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (04) :975-982
[8]   Complex karyotypes confer a poor survival in adult acute myeloid leukemia with unfavorable cytogenetic abnormalities [J].
Chen, Chih-Cheng ;
Yang, Ching-Fen ;
Lee, Kuan-Der ;
You, Jie-Yu ;
Yu, Yuan-Bin ;
Ho, Chao-Hung ;
Tzeng, Cheng-Hwai ;
Chau, Wing-Keung ;
Hsu, Hui-Chi ;
Gau, Jyh-Pyng .
CANCER GENETICS AND CYTOGENETICS, 2007, 174 (02) :138-146
[9]  
Dees EC, 2005, CLIN CANCER RES, V11, P664
[10]   G2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress [J].
Didier, C. ;
Cavelier, C. ;
Quaranta, M. ;
Galcera, M-O ;
Demur, C. ;
Laurent, G. ;
Manenti, S. ;
Ducommun, B. .
ONCOGENE, 2008, 27 (27) :3811-3820